Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurobio ScientificXPAR:ALERS +1.93%68 Net Margin % is 2.85% as of Dec. 2025, which is 14% below its 10-year median of 3.31. GuruFocus rates XPAR:ALERS with a GF Score™ of 68/100 and a GF Value™ of €25.28 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Eurobio Scientific ranks better than 52.14% on this metric.
The historical rank and industry rank for Eurobio Scientific's Net Margin % or its related term are showing as below:
XPAR:ALERS'
s Net Margin % Range Over the Past 10 Years
Min: -27.3 Med: 3.31 Max: 38.91
Current: 2.89
XPAR:ALERS's Net Margin % is ranked better than 52.14% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs XPAR:ALERS: 2.89
Eurobio Scientific (XPAR:ALERS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Eurobio Scientific Net Margin % Related Terms
Eurobio Scientific Net Margin % Historical Data
* Premium members only.
The historical data trend for Eurobio Scientific's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALERS vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Eurobio Scientific's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurobio Scientific Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eurobio Scientific's Net Margin % distribution charts can be found below:
* The bar in red indicates where Eurobio Scientific's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurobio Scientific (XPAR:ALERS) has a Net Margin % of 2.85% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Eurobio Scientific and its competitors. This is 14% below median its historical median of 3.31. According to the industry distribution chart, Eurobio Scientific ranks #391 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 47.9%.
Is Eurobio Scientific's Net Margin % too high?
Eurobio Scientific's current Net Margin % of 2.85% is 14% below median its 10-year median of 3.31. The Medical Devices & Instruments industry median Net Margin % is 2.05. Eurobio Scientific's value of 2.85% is 39% above this industry median. Based on the distribution chart, Eurobio Scientific ranks #391 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eurobio Scientific has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eurobio Scientific's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eurobio Scientific ranks #391 out of 817 companies for Net Margin %. This puts Eurobio Scientific in the upper half of its industry. The industry median Net Margin % is 2.05. Eurobio Scientific's value of 2.85% is 39% above this benchmark. While the company's 10-year median is 3.31 vs. the industry median of 2.05, Eurobio Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.05, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurobio Scientific's current Net Margin % of 2.85% is 39% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eurobio Scientific and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurobio Scientific's current Net Margin % is 2.85%, which is 14% below median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurobio Scientific stock overvalued right now?
Based on GuruFocus' analysis, Eurobio Scientific (XPAR:ALERS) is currently considered Modestly Undervalued. The stock's GF Value™ is €25.28, compared to a current price of €21.10 — trading 16.5% below its estimated fair value. The current Net Margin % is 2.85%, which is 14% below median its 10-year median of 3.31 and 39% above the Medical Devices & Instruments industry median of 2.05. Eurobio Scientific's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eurobio Scientific (XPAR:ALERS), the current Net Margin % is 2.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurobio Scientific (XPAR:ALERS) Overvalued in 2026?
Based on GuruFocus' analysis, Eurobio Scientific stock appears to be undervalued.
The current stock price of €21.10 is trading 16.5% below its estimated GF Value™ of €25.28.
GuruFocus considers Eurobio Scientific to be Modestly Undervalued.
Key valuation signals for XPAR:ALERS:
Net Margin %: 2.85% (14% below median its 10-year median of 3.31)
GF Value™: €25.28 vs. price of €21.10 (16.5% below fair value)
Industry Position: 39% above the Medical Devices & Instruments median (#391 of 817)
No single metric tells the full story. See the XPAR:ALERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.
68GF Score
Get the complete analysis for XPAR:ALERS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALERS has been successfully added to your 
